Skip to content

CorMedix CRMD Earnings yield

Earnings yield at other companies

Pfizer logo
PfizerPFE
6.8%
Merck & Co. logo
Merck & Co.MRK
3%-4.7pp
Merit Medical Systems logo
Merit Medical SystemsMMSI
3.4%+1.4pp
ITG
Integer HoldingsITGR
4.7%+2.8pp
IAR
Integra LifeSciencesIART
-67.5%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
16.1%+9.2pp

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Calculated from CorMedix’s reported figures.

Based on trailing twelve months.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's earnings yield?
CorMedix (CRMD) reported earnings yield of 33.7% in Q1 2026.
What is the long-term trend for CorMedix's earnings yield?
Over 4 years (2020 to 2025), CorMedix's earnings yield has grown at a 23.0% compound annual growth rate (CAGR), from -7.8% to 17.8%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.